A Phase 3 Randomized Study to Evaluate Survival of Patients Treated With Talaporfin Sodium (LS11) and Interstitial Light Emitting Diodes (LED) as Compared to the Standard of Care Therapies in the Treatment of Unresectable Hepatocellular Carcinoma (HCC).
Phase of Trial: Phase III
Latest Information Update: 28 Jan 2015
At a glance
- Drugs Talaporfin (Primary)
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Sponsors Light Sciences Oncology
- 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Jun 2010 Planned end date changed from 1 Nov 2008 to 1 Jun 2011 as reported by ClinicalTrials.gov.
- 20 May 2009 Additional locations identified as reported by ClinicalTrials.gov.